Trial · NCT03524092
Participant flow78
How many started, completed or left each group, period by period.
1 to 20 of 78
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Blinded Maintenance Period (Wk 0-40) | STARTED | Maintenance Period: Miri IR - Placebo (PBO) Subcutaneous (SC) | 192 | |
| Blinded Maintenance Period (Wk 0-40) | STARTED | Maintenance Period: Miri IR - 200 Milligram (mg) Miri SC | 389 | |
| Blinded Maintenance Period (Wk 0-40) | STARTED | Maintenance Period: PBO IR - PBO SC | 135 | |
| Blinded Maintenance Period (Wk 0-40) | STARTED | Loss of Response (LOR) Rescue Period:LOR Cohort-300 mg Miri IV | 0 | |
| Blinded Maintenance Period (Wk 0-40) | STARTED | Extended Induction: Induction Nonresponders - 300mg Miri IV | 0 | |
| Blinded Maintenance Period (Wk 0-40) | STARTED | Open Label Maintenance: Delayed Responders - 200 mg Miri SC | 0 | |
| Blinded Maintenance Period (Wk 0-40) | Received at Least One Dose of Study Drug | Maintenance Period: Miri IR - Placebo (PBO) Subcutaneous (SC) | 192 | |
| Blinded Maintenance Period (Wk 0-40) | Received at Least One Dose of Study Drug | Maintenance Period: Miri IR - 200 Milligram (mg) Miri SC | 389 | |
| Blinded Maintenance Period (Wk 0-40) | Received at Least One Dose of Study Drug | Maintenance Period: PBO IR - PBO SC | 135 | |
| Blinded Maintenance Period (Wk 0-40) | Received at Least One Dose of Study Drug | Loss of Response (LOR) Rescue Period:LOR Cohort-300 mg Miri IV | 0 | |
| Blinded Maintenance Period (Wk 0-40) | Received at Least One Dose of Study Drug | Extended Induction: Induction Nonresponders - 300mg Miri IV | 0 | |
| Blinded Maintenance Period (Wk 0-40) | Received at Least One Dose of Study Drug | Open Label Maintenance: Delayed Responders - 200 mg Miri SC | 0 | |
| Blinded Maintenance Period (Wk 0-40) | COMPLETED | Maintenance Period: Miri IR - Placebo (PBO) Subcutaneous (SC) | 119 | |
| Blinded Maintenance Period (Wk 0-40) | COMPLETED | Maintenance Period: Miri IR - 200 Milligram (mg) Miri SC | 347 | |
| Blinded Maintenance Period (Wk 0-40) | COMPLETED | Maintenance Period: PBO IR - PBO SC | 90 | |
| Blinded Maintenance Period (Wk 0-40) | COMPLETED | Loss of Response (LOR) Rescue Period:LOR Cohort-300 mg Miri IV | 0 | |
| Blinded Maintenance Period (Wk 0-40) | COMPLETED | Extended Induction: Induction Nonresponders - 300mg Miri IV | 0 | |
| Blinded Maintenance Period (Wk 0-40) | COMPLETED | Open Label Maintenance: Delayed Responders - 200 mg Miri SC | 0 | |
| Blinded Maintenance Period (Wk 0-40) | NOT COMPLETED | Maintenance Period: Miri IR - Placebo (PBO) Subcutaneous (SC) | 73 | |
| Blinded Maintenance Period (Wk 0-40) | NOT COMPLETED | Maintenance Period: Miri IR - 200 Milligram (mg) Miri SC | 42 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03524092/flow